Island Pharmaceuticals (ASX:ILA) Current Deferred Taxes Liabilities: A$0.00 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:ILA Island Pharmaceuticals Ltd ASX:ILA
30 GF Score
Price A$0.39
! 1 Warning Sign
View Full Analysis

What is Island Pharmaceuticals Current Deferred Taxes Liabilities?

Island Pharmaceuticals ASX:ILA +1.30% 30 Current Deferred Taxes Liabilities is A$0.00 Mil as of Dec. 2025. GuruFocus rates ASX:ILA with a GF Score™ of 30/100. The stock has 1 warning sign investors should review.

Current Deferred Taxes Liabilities represent future tax liabilities, resulting from temporary differences between book (accounting) value of assets and liabilities and their tax value, or timing differences between the recognition of gains and losses in financial statements and their recognition in a tax computation. Deferred tax liabilities generally arise where tax relief is provided in advance of an accounting expense, or income is accrued but not taxed until received.

Island Pharmaceuticals's current deferred tax liabilities for the quarter that ended in Dec. 2025 was A$0.00 Mil.

Island Pharmaceuticals Current Deferred Taxes Liabilities Related Terms

Island Pharmaceuticals Current Deferred Taxes Liabilities Historical Data

* Premium members only.

The historical data trend for Island Pharmaceuticals's Current Deferred Taxes Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Island Pharmaceuticals Current Deferred Taxes Liabilities Chart

Island Pharmaceuticals Annual Data
Trend Jun21 Jun22 Jun23 Jun24 Jun25
Current Deferred Taxes Liabilities
0.00 0.00 0.00 0.00 0.00

Island Pharmaceuticals Semi-Annual Data
Jun20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Current Deferred Taxes Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
ASX:ILA
30GF Score
Island Pharmaceuticals Ltd ASX:ILA
Current Deferred Taxes Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Current Deferred Taxes Liabilities of A$0.00 Mil mean?
Island Pharmaceuticals (ASX:ILA) has a Current Deferred Taxes Liabilities of A$0.00 Mil as of Dec. 2025. Current Deferred Tax Liabilities records the total amount of taxes due for the period but not yet paid. View historical data on Island Pharmaceuticals and its competitors.
Is Island Pharmaceuticals' Current Deferred Taxes Liabilities too high?
Island Pharmaceuticals' current Current Deferred Taxes Liabilities is A$0.00 Mil. Overall, Island Pharmaceuticals has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Island Pharmaceuticals' Current Deferred Taxes Liabilities compare to VRTX and REGN?
Island Pharmaceuticals' Current Deferred Taxes Liabilities of A$0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Taxes Liabilities for a Biotechnology company?
A good Current Deferred Taxes Liabilities depends on the Biotechnology industry context. However, Current Deferred Taxes Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Taxes Liabilities mean?
A high Current Deferred Taxes Liabilities can signal that a stock is expensive relative to its fundamentals. Current Deferred Tax Liabilities records the total amount of taxes due for the period but not yet paid. View historical data on Island Pharmaceuticals and its competitors. Island Pharmaceuticals's current Current Deferred Taxes Liabilities is A$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Island Pharmaceuticals stock overvalued right now?
Island Pharmaceuticals (ASX:ILA) has a current Current Deferred Taxes Liabilities of A$0.00 Mil. The current Current Deferred Taxes Liabilities is A$0.00 Mil. Island Pharmaceuticals' overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Taxes Liabilities calculated?
Current Deferred Taxes Liabilities is calculated from a company's financial statements. For Island Pharmaceuticals (ASX:ILA), the current Current Deferred Taxes Liabilities is A$0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Island Pharmaceuticals Business Description

Address c/- Bio101 Financial Advisory Pty Ltd, 697 Burke Road, Suite 201, Camberwell, Melbourne, VIC, AUS, 3124
Island Pharmaceuticals Ltd is a drug research and repurposing company focused on developing preventative or therapeutic drugs for viral infections, public health, or biosecurity threats. The company is following a dual development plan for its assets, ISLA-101 and Galidesivir. Its product candidate, ISLA-101, is being repurposed for the prevention and treatment of dengue fever and other mosquito-borne (or vector) borne diseases. Galidesivir is a clinical-stage antiviral molecule with a broad spectrum of activity in over 20 RNA viruses, including high-priority threats such as Ebola, Marburg, MERS, Zika, and Yellow fever viruses, with unmet medical needs. The company operates in a single segment, being research and development activities in Australia and the United States of America.
30GF Score

Get the complete analysis for ASX:ILA

Current Deferred Taxes Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.39
Price